25 September 2023
EMA/PRAC/355801/2023
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 25-28 September 2023

Chair: Sabine Straus – Vice-Chair: Martin Huber

25 September 2023, 13:00 – 19:30, room 1C / via teleconference

26 September 2023, 08:30 – 19:30, room 1C / via teleconference

27 September 2023, 08:30 – 19:30, room 1C / via teleconference

28 September 2023, 08:30 – 16:00, room 1C / via teleconference

Organisational, regulatory and methodological matters (ORGAM)

12 October 2023, 09:00 - 12:00, via teleconference

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 25-28 September 2023. See October 2023 PRAC minutes (to be published post November 2023 PRAC meeting).

1.2. Agenda of the meeting on 25-28 September 2023

Action: For adoption

1.3. Minutes of the previous meeting on 28-31 August 2023

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

3.2.1. Hydroxyprogesterone (NAP) - EMEA/H/A-31/1528

Applicant(s): various

PRAC Rapporteur: Amelia Cupelli; PRAC Co-rapporteur: Nathalie Gault

Scope: Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a list of outstanding issues (LoOI)

3.2.2. Pseudoephedrine (NAP); pseudoephedrine, acetylsalicylic acid (NAP); pseudoephedrine, acetylcysteine, paracetamol (NAP); pseudoephedrine, acrivastine (NAP); pseudoephedrine, ascorbic acid, paracetamol (NAP); pseudoephedrine, cetirizine (NAP); pseudoephedrine, ebastine (NAP); pseudoephedrine, guaifenesin (NAP); pseudoephedrine, ibuprofen (NAP); pseudoephedrine, chlorphenamine (NAP); pseudoephedrine, chlorphenamine, codeine (NAP); pseudoephedrine, chlorphenamine, dextromethorphan (NAP); pseudoephedrine, chlorphenamine, paracetamol (NAP); pseudoephedrine, chlorphenamine, dextromethorphan, paracetamol (NAP); pseudoephedrine, dextromethorphan (NAP); pseudoephedrine, dextromethorphan, paracetamol (NAP); pseudoephedrine, dextromethorphan, ascorbic acid, paracetamol (NAP); pseudoephedrine, dextromethorphan, guaifenesin, paracetamol (NAP); pseudoephedrine, dextromethorphan, guaifenesin, triprolidine (NAP); pseudoephedrine, dextromethorphan, triprolidine (NAP); pseudoephedrine, diphenhydramine, paracetamol (NAP); pseudoephedrine, doxylamine, paracetamol (NAP); pseudoephedrine, loratadine (NAP); pseudoephedrine, paracetamol (NAP); pseudoephedrine, paracetamol, pholcodine (NAP); pseudoephedrine, triprolidine (NAP); pseudoephedrine, triprolidine, guaifenesin (NAP); pseudoephedrine, triprolidine, paracetamol (NAP); pseudoephedrine, desloratadine – AERINAZE (CAP) – EMA/H/A-31/1526

Applicant(s): various

PRAC Rapporteur: Eva Jirsová; PRAC Co-rapporteur: Maia Uusküla

Scope: Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: Feedback from the ad-hoc expert group (AHEG) meeting and adoption of a list of outstanding issues (LoOI) or PRAC recommendation to CHMP

3.3. Procedures for finalisation

3.4. Re-examination procedures[1]

None

3.5. Others

None

[1] Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC

4. Signals assessment and prioritisation[2]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Abemaciclib – VERZENIOS (CAP), Palbociclib – IBRANCE (CAP), Ribociclib – KISQALI (CAP)

Applicant(s): Eli Lilly Nederland B.V. (Verzenios), Pfizer Europe MA EEIG, Novartis Europharm Limited (Kisqali)

PRAC Rapporteur: to be appointed

Scope: Signal of erythema multiforme

Action: For adoption of PRAC recommendation

EPITT 19973 – New signal

Lead Member State(s): DK

4.1.2. Chlorhexidine (NAP)[3] and other relevant fixed-dose combinations[4]

Applicant: various

PRAC Rapporteur: to be appointed

Scope: Signal of persistent corneal injury and significant visual impairment

Action: For adoption of PRAC recommendation

EPITT 19970 – New signal

Lead Member State(s): LT

4.1.3. Chlorhexidine gluconate, isopropyl alcohol (NAP); chlorhexidine digluconate, isopropyl alcohol (NAP)

Applicant: various

PRAC Rapporteur: to be appointed

[2] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

[3] For cutaneous use only

[4] Chlorhexidine, chlorocresol, hexamidine; chlorhexidine gluconate, chlorocresol, hexamidine; chlorocresol, hexamidine, chlorhexidine digluconate; benzalkonium chloride, chlorhexidine gluconate; chlorhexidine gluconate, benzoxonium chloride, retinol; benzalkonium chloride, chlorhexidine gluconate, benzyl alcohol; chlorhexidine gluconate; chlorhexidine gluconate, cetrimonium; chlorhexidine gluconate, chlorocresol, hexamidine; chlorhexidine gluconate, dexpanthenol; chlorhexidine gluconate, hydrocortisone; chlorhexidine gluconate, hydrogen peroxide, isopropyl alcohol; chlorhexidine gluconate, isopropyl alcohol; chlorhexidine gluconate, ethanol; chlorhexidine gluconate, phenol; benzalkonium chloride, chlorhexidine gluconate; benzalkonium chloride, chlorhexidine digluconate; chlorhexidine digluconate; chlorhexidine digluconate, ethanol; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine dihydrochloride; benzalkonium chloride, chlorhexidine dihydrochloride, isopropyl myristate, liquid paraffin; chlorhexidine dihydrochloride, dexpanthenol; chlorhexidine dihydrochloride, nystatin; chlorhexidine dihydrochloride, nystatin, dexamethasone; chlorhexidine dihydrochloride, nystatin, hydrocortisone; chlorhexidine dihydrochloride, zinc oxide, pramocaine hydrochloride;, triamcinolone acetonide; chlorhexidine dihydrochloride, dexpanthenol, alphatocopherol acetate, vitamin A; chlorhexidine gluconate; cetrimide, chlorhexidine digluconate; chlorhexidine acetate; cetrimide, chlorhexidine acetate; retinol palmitate, chlorhexidine acetate; retinol palmitate, benzocaine, retinol, chlorhexidine acetate; bacitracin zinc, chlorhexidine acetate; nystatin, hydrocortisone, chlorhexidine acetate.

Scope: Signal of product caught fire

Action: For adoption of PRAC recommendation

EPITT 19969 – New signal

Lead Member State(s): BE

4.1.4. Glucagon-like peptide-1 (GLP-1) receptor agonists: dulaglutide – TRULICITY (CAP); exenatide – BYDUREON (CAP), BYETTA (CAP); insulin degludec, liraglutide – XULTOPHY (CAP); liraglutide – SAXENDA (CAP), VICTOZA (CAP); insulin glargine, lixisenatide – SULIQUA (CAP); lixisenatide - LYXUMIA (CAP); semaglutide – OZEMPIC (CAP), RYBELSUS (CAP), WEGOVY (CAP); tirzepatide – MOUNJARO (CAP)

Applicant: AstraZeneca AB (Bydureon, Byetta), Eli Lilly Nederland B.V. (Trulicity), Novo Nordisk A/S (Ozempic, Rybelsus, Saxenda, Victoza, Wegovy, Xultophy), Sanofi Winthrop Industrie (Lyxumia, Suliqua)

PRAC Rapporteur: to be appointed

Scope: Signal of aspiration and pneumonia aspiration

Action: For adoption of PRAC recommendation

EPITT 19974 – New signal

Lead Member State(s): SE

4.1.5. Teriparatide – FORSTEO (CAP), MOVYMIA (CAP), TERROSA (CAP), LIVOGIVA (CAP), SONDELBAY (CAP), KAULIV (CAP), TERIPARATIDE SUN (CAP); NAP

Applicant: Accord Healthcare S.L.U. (Sondelbay), Eli Lilly Nederland B.V. (Forsteo), Gedeon Richter Plc. (Terrosa), STADA Arzneimittel AG (Movymia), Strides Pharma (Cyprus) Limited (Kauliv), Sun Pharmaceutical Industries Europe B.V. (Teriparatide SUN), Theramex Ireland Limited (Livogiva)

PRAC Rapporteur: to be appointed

Scope: Signal of alopecias

Action: For adoption of PRAC recommendation

EPITT 19972 – New signal

Lead Member State(s): FR

4.2. New signals detected from other sources

None

4.3. Signals follow-up and prioritisation

4.3.1. Azacitidine – AZACITIDINE ACCORD (CAP), AZACITIDINE BETAPHARM (CAP), AZACITIDINE MYLAN (CAP), ONUREG (CAP) - EMEA/H/C/004761/SDA/002; VIDAZA (CAP) - EMEA/H/C/003820/SDA/036

Applicant(s): Accord Healthcare S.L.U. (Azacitidine Accord), betapharm Arzneimittel GmbH (Azacitidine betapharm), Bristol-Myers Squibb Pharma EEIG (Onureg, Vidaza), Mylan Ireland Limited (Azacitidine Mylan)

PRAC Rapporteur: Menno van der Elst

Scope: Signal of Cutaneous Vasculitis

Action: For adoption of PRAC recommendation

EPITT 19929 – follow up to May 2023

4.3.2. Baricitinib – OLUMIANT (CAP) - EMEA/H/C/004085/SDA/017

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Signal of interstitial lung disease

Action: For adoption of PRAC recommendation

EPITT 19913 – follow up to May 2023

4.3.3. Rituximab – BLITZIMA (CAP) - EMEA/H/C/004723/SDA/005, MABTHERA (CAP) - EMEA/H/C/000165/SDA/200, RIXATHON (CAP) - EMEA/H/C/003903/SDA/006, RIXIMYO (CAP) - EMEA/H/C/004729/SDA/006, RUXIENCE (CAP) - EMEA/H/C/004696/SDA/003, TRUXIMA (CAP) -EMEA/H/C/004112/SDA/005

Applicant: Celltrion Healthcare Hungary Kft. (Blitzima, Truxima), Pfizer Europe MA EEIG (Ruxience), Roche Registration GmbH (MabThera), Sandoz GmbH (Rixathon, Riximyo)

PRAC Rapporteur: Karin Susanne Lindenstrom Erneholm

Scope: Signal of oral lichenoid reaction

Action: For adoption of PRAC recommendation

EPITT 19916 – follow up to May 2023

4.4. Variation procedure(s) resulting from signal evaluation

None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Concizumab - EMEA/H/C/005938

Scope: Routine prophylaxis to prevent or reduce the frequency of bleeding in patients with haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors ≥ 12 years of age and haemophilia B (congenital factor IX deficiency) with FIX inhibitors of any age

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Dopamine hydrochloride - EMEA/H/C/006044, PUMA[5]

Scope: Treatment of hypotension in neonates, infants and children

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Epinephrine - EMEA/H/C/006139

Scope: Treatment of allergic reactions (anaphylaxis) and idiopathic or exercise induced anaphylaxis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Etrasimod - EMEA/H/C/006007

Scope: Treatment of patients with moderately to severely active ulcerative colitis (UC)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Germanium (^{68}Ge) chloride, gallium (^{68}Ga) chloride - EMEA/H/C/005165

Scope: Indicated for in vitro labelling of kits for radiopharmaceutical preparation

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Omaveloxolone - EMEA/H/C/006084, Orphan

Applicant: Reata Ireland Limited

Scope: Treatment of Friedreich's ataxia

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Pegcetacoplan - EMEA/H/C/005954

Scope: Treatment of geographic atrophy (GA) secondary to age-related macular

[5] Paediatric use marketing authorisation(s)

degeneration (AMD)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Toripalimab - EMEA/H/C/006120

Scope: Combination treatment for metastatic or recurrent locally advanced nasopharyngeal carcinoma and for metastatic or recurrent oesophageal squamous cell carcinoma

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Benralizumab - FASENRA (CAP) - EMEA/H/C/004433/II/0049/G

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Grouped application consisting of: 1) Submission of an updated RMP version 5 in order to remove the safety concern of missing information on use in pregnant and lactating women. Consequently, the MAH proposes to remove study D3250R00026 as an additional pharmacovigilance activity, and to remove the commitment to conduct additional pharmacovigilance for the use of benralizumab in pregnant and lactating women with severe eosinophilic asthma; 2) Submission of an updated RMP version 5 in order to remove the safety concern of important potential risk of serious infections

Action: For adoption of PRAC Assessment Report

5.2.2. Dapagliflozin - EDISTRIDE (CAP) - EMEA/H/C/004161/WS2517/0063; FORXIGA (CAP) - EMEA/H/C/002322/WS2517/0084

Applicant: AstraZeneca AB

PRAC Rapporteur: Mari Thorn

Scope: Submission of an updated RMP version 30 in order to remove the potential important risk for lower limb amputation

Action: For adoption of PRAC Assessment Report

5.2.3. Deferasirox - EXJADE (CAP) - EMEA/H/C/000670/II/0085

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Tiphaine Vaillant

Scope: Submission of an updated RMP version 21.0 in order to include the physician survey CICL670A2429 as a PASS category 3, based on the submission of a draft version of the protocol for the physician survey CICL670A2429. The Annex IID is updated to remove one sentence related to 'surveillance programme' and to introduce a minor correction

Action: For adoption of PRAC Assessment Report

5.2.4. Doxorubicin - CAELYX PEGYLATED LIPOSOMAL (CAP) - EMEA/H/C/000089/II/0107

Applicant: Baxter Holding B.V.

PRAC Rapporteur: Eva Jirsová

Scope: Submission of an updated RMP version 6.1 in order to align to GVP Module V Revision 2 requirements, following a request received within the Assessment Report for procedure EMEA/H/C/PSUSA/00001172/202111

Action: For adoption of PRAC Assessment Report

5.2.5. Rilpivirine - REKAMBYS (CAP) - EMEA/H/C/005060/II/0019

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of an updated RMP version 4.1 in order to update the risk characterisation information for the missing information 'use in pregnancy' based on interim data of the Antiretroviral Pregnancy Register (APR), listed as a category 3 study in the RMP; and to align the milestones and due dates of this study following the outcome of procedure EMEA/H/C/PSUSA/00010901/202209. In addition, the MAH took the opportunity to update the status and the interim report milestones for the studies DUS and COMBINE-2

Action: For adoption of PRAC Assessment Report

5.2.6. Tecovirimat - TECOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/II/0006

Applicant: SIGA Technologies Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of substantial updates to the protocol of study SIGA-246-021 listed as a specific obligation in the Annex II of the product information in order to reflect the transfer of sponsorship from SIGA Technologies, Inc. to the NIH Division of Microbiology and Infection Disease protocol. This is a phase 4, observational field study to evaluate safety and clinical benefit in tecovirimat-treated patients following exposure to variola virus and clinical diagnosis of smallpox disease. The Annex II and the RMP submitted version 1.2 are updated accordingly

Action: For adoption of PRAC Assessment Report

5.2.7. Velaglucerase alfa - VPRIV (CAP) - EMEA/H/C/001249/II/0061

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP version 12.0 in order to remove certain risks from the list of safety concerns

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/II/0152

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include the prophylaxis of acute Graft versus Host Disease (aGvHD) in the adult and paediatric population for Orencia, based on final results from studies IM101311 - Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis and IM101841 - Overall Survival In 7/8 HLA-Matched Hematopoietic Stem Cell Transplantation Patients Treated With Abatacept Combined With A Calcineurin Inhibitor And Methotrexate - An Analysis Of The Center For International Blood And Marrow Transplant Research (Cibmtr) database. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and Labelling are updated in accordance. Version 28.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Adalimumab - AMGEVITA (CAP) - EMEA/H/C/004212/X/0036/G

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Extension application to introduce a new strength, 80 mg [0.8 ml (100 mg/ml)] solution for injection, grouped with various quality variations:

- B.II.a.5 (type II) - To introduce a high-concentration formulation (100 mg/ml) to the already existing concentration (50 mg/ml) where the amount of AS per unit dose (i.e. the strength, 20 mg, 40 mg) remains the same. The new pack-size of 1 in pre-filled syringe (glass) in 20 mg /0.2ml solution for injection is consequently introduced.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 1 pre-filled syringe (glass) in 40mg /0.4ml Solution for injection.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 2 pre-filled syringe (glass) in 40mg /0.4ml Solution for injection.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 6 (3 x 2) in pre-filled syringe (glass) (multipack) in 40mg /0.4ml Solution for injection.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 1 pre-filled syringe (glass) in pre-filled pen (SureClick) in 40mg /0.4ml Solution for injection.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 2 pre-filled syringe (glass) in pre-filled pen (SureClick) in 40mg /0.4ml Solution for injection.
- B.II.e.5.a.1 (type IAIN) - To introduce the new pack-size of 6 (3 x 2) pre-filled syringe (glass) (multipack) in pre-filled pen (SureClick) in 40mg /0.4ml Solution for injection.
- B.II.f.1.b.5 (type IB) - To extend the shelf-life of the 50 mg/ml finished product, in accordance with the approved stability protocol, from 24 months to 36 months. The shelf-life is aligned with the proposed shelf life for the 100 mg/ml finished product.
- B.I.a.2.a (type IB) - Minor changes in the manufacturing process of the active substance formulation (applies to both 50 mg/ml and 100 mg/ml) Additionally, editorial

changes are introduced to update method number updates. The RMP (version 6.0) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Aflibercept - EYLEA (CAP) - EMEA/H/C/002392/X/0084/G

Applicant: Bayer AG

PRAC Rapporteur: Nathalie Gault

Scope: Extension application to add a new strength of Aflibercept 114.3 mg/ml solution for injection (in a vial), to be indicated in adults for the (1) treatment of neovascular (wet) age-related macular degeneration (nAMD) and (2) visual impairment due to diabetic macular oedema (DME), grouped with a type II variation (B.II.g.2) to introduce a post-approval change management protocol to add a new presentation for Aflibercept solution 114.3 mg/ml in a single-use pre-filled syringe for intravitreal injection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0094

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: Update of section 4.2 of the SmPC in order to add home infusion upon request by PRAC following the assessment of PSUSA/00000086/202109 based on a cumulative search of the MAH Global Pharmacovigilance database and literature. The package leaflet and Annex II are updated accordingly. The RMP version 10.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Bezlotoxumab - ZINPLAVA (CAP) - EMEA/H/C/004136/II/0037

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension of indication to include treatment of the paediatric population (1 to 18 years of age) for ZINPLAVA, based on final results from study MK-6072-001 (MODIFY III) listed as a category 3 study in the RMP; this is a phase 3, randomised, placebo-controlled, parallel-group, multi-site, double-blind trial evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of a single infusion of bezlotoxumab in paediatric participants from 1 to <18 years of age receiving antibacterial drug treatment for Clostridioides difficile infection (CDI). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/II/0020

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults, based on final results from study HS0003 (BE HEARD I) and study HS0004 (BE HEARD II). These are phase 3, randomised, double blind, placebo controlled, multicentre, pivotal studies evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe HS. Further supportive data are based on the results of phase 2 study HS0001 and phase 3 currently ongoing open-label extension study HS0005. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.10 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD template version 10.3

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. Brentuximab vedotin - ADCETRIS (CAP) - EMEA/H/C/002455/II/0109, Orphan

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) for ADCETRIS based on the final overall survival results of Echelon-2 (SGN035-014): a randomised, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 19.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.8. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/II/0039, Orphan

Applicant: BioMarin International Limited

PRAC Rapporteur: Mari Thorn

Scope: Update of sections 4.2, 4.4, 4.8, 5.1, 5.2, 6.5 and 9 of the SmPC in order to state that clinical data are available for patients aged 1 year and older and to include updates to the frequency of adverse reactions, immunogenicity, pharmacokinetic, and paediatric population sections based on the final results from studies 190-203, listed as a specific obligation and 190-202 (submitted in P46/013). Study 190-203 was a phase 2, open-label, multicentre study in paediatric patients < 18 years of age with CLN2 disease, confirmed by deficiency of TPP1 enzyme activity and mutation of the CLN2 gene. The package leaflet, Annex II and Annex IV are updated accordingly. The RMP version 4.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Crizotinib - XALKORI (CAP) - EMEA/H/C/002489/X/0080/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Extension application to introduce a new pharmaceutical form (granules in capsules for opening) associated with new strengths (20, 50 and 150 mg), grouped with a type II variation (C.I.6.a) to include the treatment of paediatric patients with relapsed or refractory, systemic ALK-positive ALCL or unresectable, recurrent, or refractory ALK-positive IMT to change the lower end of the age range from ≥6 years to ≥1 year for Xalkori following the assessment of II/0072 based on final results from study ADVL0912. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/II/0023

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Extension of indication to include in combination with platinum-containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy, based on results from study 213361 (RUBY) Part 1, listed as a Specific Obligation in the Annex II; this is a phase 3, randomised, double-blind, multicentre study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and package leaflet are updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information. As part of the application, the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Edoxaban - LIXIANA (CAP) - EMEA/H/C/002629/WS2409/0042; ROTEAS (CAP) - EMEA/H/C/004339/WS2409/0029

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Nathalie Gault

Scope: Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC with available paediatric data based on final results from study DU176b-D-U312; this is a phase 3, open-label, randomised, multicentre, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard-of-care anticoagulant therapy in paediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism (VTE). The package leaflet and labelling are updated accordingly. The RMP version 15.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to

bring the product information in line with the latest QRD template version 10.3

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/II/0006, Orphan

Applicant: Argenx

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on use of vaccination and update drug-drug interaction information on vaccines based on final results from study ARGX-113-2102: a phase 1, randomised, open-label, placebo-controlled, parallel-group study to evaluate the immune response to PNEUMOVAX 23 in healthy participants receiving efgartigimod IV 10 mg/kg or placebo. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Florbetapir (^{18}F) - AMYVID (CAP) - EMEA/H/C/002422/II/0044

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.4 of the SmPC in order to remove the limitation regarding monitoring response to therapy based on available information in the scientific literature. The RMP version 4.1 has also been submitted. In addition, the MAH took the opportunity to update section 4.8 to the SmPC to align the clinical trial exposures with the RMP

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Gilteritinib - XOSPATA (CAP) - EMEA/H/C/004752/II/0013, Orphan

Applicant: Astellas Pharma Europe B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of sections 4.2 and 5.2 in order to update the information on renal impairment based on final results from study 2215-CL-0114, listed as a category 3 study in the RMP. Study 2215-CL-0114 is a phase 1, single-dose, open-label study to investigate the effect of renal impairment on gilteritinib pharmacokinetics, safety and tolerability in 9 participants with severe renal impairment compared to 8 participants with normal renal function. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Ibandronic acid - BONDRONAT (CAP) - EMEA/H/C/000101/WS2451/0090; BONVIVA (CAP) - EMEA/H/C/000501/WS2451/0075

Applicant: Atnahs Pharma Netherlands B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add information regarding the risk of 'atypical fractures of long bones other than femour' based on literature. The package leaflet is updated accordingly. The RMP version 3.1 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/II/0038, Orphan

Applicant: Akcea Therapeutics Ireland Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to modify the warning on liver monitoring and drug-induced liver injury and to add 'drug-induced liver injury' to the list of adverse drug reactions (ADRs) with frequency 'not known', following the request in the assessment report for PAM procedure EMEA/H/C/004782/LEG/008. The Annex II and package leaflet are updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor updates to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Irinotecan hydrochloride trihydrate - ONIVYDE PEGYLATED LIPOSOMAL (CAP) - EMEA/H/C/004125/II/0034, Orphan

Applicant: Les Laboratoires Servier

PRAC Rapporteur: David Olsen

Scope: Extension of indication to include first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas for Onivyde in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) based on final results from phase 3 study NAPOLI 3 (D-US-60010-001): an interventional study with a primary objective to evaluate the efficacy of the regimen of irinotecan liposome injection + oxaliplatin + 5-fluorouracil (5-FU)/leucovorin (LV) versus nab-paclitaxel + gemcitabine in improving overall survival (OS) in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. The updated RMP version 4.1 is also submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0021, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Jo Robays

Scope: Extension of indication to include treatment of adult patients with anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS), who may require RBC transfusions for Reblozyl, based on results from study ACE-536-MDS-002 (COMMANDS), an active-controlled, open-label, randomised phase 3 study comparing the

efficacy and safety of luspatercept vs epoetin alfa in adult subjects with anaemia due to IPSS-R very low, low or intermediate risk MDS, who are ESA naïve and require RBC transfusions, and studies ACE-536-MDS-001(MEDALIST), ACE-536-MDS-004 , A536-03, A536-05 and ACE-536-LTFU-001. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Meningococcal group A, C, W135 and Y conjugate vaccine - MENVEO (CAP) - EMEA/H/C/001095/X/0119

Applicant: GSK Vaccines S.r.l

PRAC Rapporteur: Menno van der Elst

Scope: Extension application to introduce a new pharmaceutical form (solution for injection). The RMP (version 11.0) is updated in accordance.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Meropenem, vaborbactam - VABOREM (CAP) - EMEA/H/C/004669/II/0020

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of the final reports from Global Microbiology Surveillance Study and Molecular Surveillance Report, listed as a category 3 study in the RMP. The RMP version 2.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Nirsevimab - BEYFORTUS (CAP) - EMEA/H/C/005304/II/0005

Applicant: AstraZeneca AB

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe respiratory syncytial virus (RSV) disease through their second RSV season for BEYFORTUS, based on interim results from studies D5290C00005 and D5290C00008. Study D5290C00005 (MEDLEY) is a phase II/III, randomised, double-blind, placebo-controlled study to evaluate the safety of Beyfortus in high-risk children. Study D5290C00008 (MUSIC) is a phase II, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, and occurrence of antidrug antibody for Beyfortus in immunocompromised children $\leqslant$ 24 Months of Age. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC are updated. The package leaflet is updated accordingly. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Osimertinib - TAGRISSO (CAP) - EMEA/H/C/004124/II/0052

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Update of section 5.1 of the SmPC in order to update efficacy information (final OS data) based on final results from study D5164C00001 (ADAURA) listed as a post-authorisation efficacy study (PAES) in the Annex II: a phase III, double-blind, randomised, placebo-controlled study, designed to assess the efficacy and safety of osimertinib versus placebo in patients with stage IB-IIIA epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC) who have undergone complete tumour resection, with or without postoperative adjuvant chemotherapy. The RMP version 15 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the product information and to implement editorial changes to the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Patisiran - ONPATTRO (CAP) - EMEA/H/C/004699/II/0034, Orphan

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the final report from study ALN-TTR02-006 (study 006), listed a category 3 study in the RMP. This is a multicentre, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. The RMP version 2.2 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Sapropterin - KUVAN (CAP) - EMEA/H/C/000943/II/0078

Applicant: BioMarin International Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the final report from study KOGNITO, listed as a category 3 study in the RMP. This is a phase IV open-label, single-cohort study of the long-term neurocognitive outcomes in 4- to 5-year old children with phenylketonuria treated with sapropterin dihydrochloride (Kuvan) for 7 years. The RMP version 16.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Talazoparib - TALZENNA (CAP) - EMEA/H/C/004674/X/0015/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Grouped application consisting of: 1) addition of a new strength of 0.1 mg hard capsules; 2) extension of indication to add talazoparibin combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), based on final results from study C3441021 (TALAPRO-2) as well as supplemental

data from study C3441006 (TALAPRO-1). Study C3441021 (TALAPRO-2) is a randomised, double-blind, placebo-controlled, phase 3 study of talazoparib in combination with enzalutamide in mCRPC, while study C3441006 (TALAPRO-1) is a phase 2, open-label, response rate study of talazoparib in men with DNA repair defects and mCRPC who previously received taxane-based chemotherapy and progressed on at least one novel hormonal agent. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.5, 4.7, 4.8, 5.1, 5.2, 6.1, 6.5, 8 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Tenofovir alafenamide - VEMLIDY (CAP) - EMEA/H/C/004169/II/0043/G

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Valentina Di Giovanni

Scope: Grouped application consisting of 1) submission of the final report from study GS-US-320-0108 listed as category 3 studies in the RMP: a phase 3, randomised, double-blind study to evaluate the safety and efficacy of tenofovir alafenamide (TAF) 25 mg QD versus tenofovir disoproxil fumarate (TDF) 300 mg QD for the treatment of HBeAg-negative, chronic hepatitis B. The RMP version 10.1 has also been submitted; 2) submission of the final report from study GS-US-320-0110 listed as category 3 studies in the RMP: a phase 3, randomised, double-blind study to evaluate the safety and efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B. The RMP version 10.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Vonicog alfa - VEYVONDI (CAP) - EMEA/H/C/004454/II/0030

Applicant: Baxalta Innovations GmbH

PRAC Rapporteur: Mari Thorn

Scope: Extension of indication to include prophylactic treatment to prevent or reduce the frequency of bleeding episodes based on final results from study 071301 and interim results from study SHP677-304. Study 071301 is a prospective, phase 3, open-label, international multicentre study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand disease; while study SHP677-304 is a phase 3B, prospective, open-label, uncontrolled, multicentre study on long term safety and efficacy of rVWF in paediatric and adult subjects with severe von Willebrand disease. As a consequence, sections 4.1, 4.2, 4.4, 5.1, 5.2, 6.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Zanubrutinib - BRUKINSA (CAP) - EMEA/H/C/004978/II/0014

Applicant: BeiGene Ireland Ltd

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include zanubrutinib in combination with obinutuzumab treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic treatments for BRUKINSA, based on results from studies BGB-3111-212 and BGB-3111-GA101-001. BGB-3111-212 is an ongoing international, Phase 2, open-label, randomised (2:1), active control study of zanubrutinib plus obinutuzumab (Arm A) versus obinutuzumab monotherapy (Arm B) in patients with R/R FL. The primary efficacy endpoint is overall response rate (ORR); while BGB-3111-GA101-001 is a Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-Cell Lymphoid Malignanciesa. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Abrocitinib - CIBINQO (CAP) - PSUSA/00010976/202303

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Apalutamide - ERLEADA (CAP) - PSUSA/00010745/202302

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Baloxavir marboxil - XOFLUZA (CAP) - PSUSA/00010895/202302

Applicant: Roche Registration GmbH

PRAC Rapporteur: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.4. Baricitinib - OLUMIANT (CAP) - PSUSA/00010578/202302

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.5. Bedaquiline - SIRTURO (CAP) - PSUSA/00010074/202303

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.6. Bempedoic acid - NILEMDO (CAP); bempedoic acid, ezetimibe - NUSTENDI (CAP) - PSUSA/00010841/202302

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Bimekizumab - BIMZELX (CAP) - PSUSA/00010953/202302

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.8. Burosumab - CRYSVITA (CAP) - PSUSA/00010669/202302

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.9. Ceftazidime, avibactam - ZAVICEFTA (CAP) - PSUSA/00010513/202302

Applicant: Pfizer Ireland Pharmaceuticals

PRAC Rapporteur: Rugile Pilviniene

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Ciltacabtagene autoleucel - CARVYKTI (CAP) - PSUSA/00011000/202302

Applicant: Janssen-Cilag International NV, ATMP[6]

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.11. Colistimethate sodium[7] - COLOBREATHE (CAP) - PSUSA/00009112/202302

Applicant: Teva B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - JCOVDEN (CAP) - PSUSA/00010916/202302

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Coronavirus (COVID-19) vaccine (inactivated, adjuvanted, adsorbed) - COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA (CAP) - PSUSA/00011001/202302

Applicant: Valneva Austria GmbH

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.14. Dengue tetravalent vaccine (live, attenuated) - DENGUE TETRAVALENT VACCINE (Art 58[8]) - EMEA/H/W/005362/PSUV/0004

Applicant: Takeda GmbH

PRAC Rapporteur: Menno van der Elst

[6] Advanced therapy medicinal product
[7] Dry inhalation powder only
[8] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

Scope: Evaluation of a PSUR procedure

Action: For adoption of recommendation to CHMP

6.1.15. Dengue tetravalent vaccine[9] (live, attenuated) - QDENGA (CAP) - PSUSA/00011034/202302

Applicant: Takeda GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.16. Difelikefalin - KAPRUVIA (CAP) - PSUSA/00010995/202302

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.17. Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), haemophilus type b conjugate vaccine (adsorbed) - VAXELIS (CAP) - PSUSA/00010469/202302

Applicant: MCM Vaccine B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.18. Emtricitabine, rilpivirine, tenofovir alafenamide - ODEFSEY (CAP) - PSUSA/00010514/202302

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. Epoetin beta - NEORECORMON (CAP) - PSUSA/00001239/202302

Applicant: Roche Registration GmbH

PRAC Rapporteur: Martin Huber

[9] Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Eptinezumab - VYEPTI (CAP) - PSUSA/00010966/202302

Applicant: H. Lundbeck A/S

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Esketamine[10] - SPRAVATO (CAP) - PSUSA/00010825/202303

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Kirsti Villikka

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Etanercept - BENEPALI (CAP); ENBREL (CAP); ERELZI (CAP); NEPEXTO (CAP) - PSUSA/00010795/202302

Applicant: Samsung Bioepis NL B.V. (Benepali), Pfizer Europe MA EEIG (Enbrel), Sandoz GmbH (Erelzi), Biosimilar Collaborations Ireland Limited (Nepexto)

PRAC Rapporteur: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Evinacumab - EVKEEZA (CAP) - PSUSA/00010945/202302

Applicant: Ultragenyx Germany GmbH

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Ex vivo expanded autologous human corneal epithelial cells containing stem cells - HOLOCLAR (CAP) - PSUSA/00010352/202302

Applicant: Holostem Terapie Avanzate s.r.l., ATMP[11]

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

[10] Centrally authorised product(s) only
[11] Advanced therapy medicinal product

Action: For adoption of recommendation to CAT and CHMP

6.1.25. Fampridine - FAMPYRA (CAP) - PSUSA/00001352/202301

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Fedratinib - INREBIC (CAP) - PSUSA/00010909/202302

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Ferric maltol - FERACCRU (CAP) - PSUSA/00010476/202302

Applicant: Norgine B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Florbetaben (^{18}F) - NEURACEQ (CAP) - PSUSA/00010094/202302

Applicant: Life Radiopharma Berlin GmbH

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Fosdenopterin - NULIBRY (CAP) - PSUSA/00011017/202302

Applicant: TMC Pharma (EU) Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Imlifidase - IDEFIRIX (CAP) - PSUSA/00010870/202302

Applicant: Hansa Biopharma AB

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.31. Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - PSUSA/00010300/202303

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.32. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - FLUCELVAX TETRA (CAP) - PSUSA/00010737/202303

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.33. Isatuximab - SARCLISA (CAP) - PSUSA/00010851/202303

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.34. Ivacaftor - KALYDECO (CAP) - PSUSA/00009204/202301

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.35. Lenacapavir - SUNLENCA (CAP) - PSUSA/00011012/202302

Applicant: Gilead Sciences Ireland Unlimited Company

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.36. Lonapegsomatropin - SKYTROFA (CAP) - PSUSA/00010969/202302

Applicant: Ascendis Pharma Endocrinology Division A/S

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Mitapivat - PYRUKYND (CAP) - PSUSA/00011025/202302

Applicant: Agios Netherlands B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - MOSQUIRIX (Art 58[12]) - EMEA/H/W/002300/PSUV/0071

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Jean-Michel Dogné; PRAC Co-rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUR procedure

Action: For adoption of recommendation to CHMP

6.1.39. Pralsetinib - GAVRETO (CAP) - PSUSA/00010961/202303

Applicant: Roche Registration GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.40. Pregabalin - LYRICA (CAP); PREGABALIN PFIZER (CAP) - PSUSA/00002511/202301

Applicant: Upjohn EESV

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.41. Pretomanid - DOVPRELA (CAP) - PSUSA/00010863/202302

Applicant: Mylan IRE Healthcare Limited

[12] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.42. Rasburicase - FASTURTEC (CAP) - PSUSA/00002613/202302

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.43. Ribociclib - KISQALI (CAP) - PSUSA/00010633/202303

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.44. Rimegepant - VYDURA (CAP) - PSUSA/00010997/202302

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.45. Risperidone[13] - OKEDI (CAP) - PSUSA/00010985/202302

Applicant: Laboratorios Farmaceuticos Rovi S.A.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.46. Ropeginterferon alfa-2b - BESREMI (CAP) - PSUSA/00010756/202302

Applicant: AOP Orphan Pharmaceuticals GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

[13] Centrally authorised product(s) only

6.1.47. Rotigotine - NEUPRO (CAP) - PSUSA/00002667/202302

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.48. Ruxolitinib - JAKAVI (CAP) - PSUSA/00010015/202302

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.49. Safinamide - XADAGO (CAP) - PSUSA/00010356/202302

Applicant: Zambon S.p.A.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.50. Silodosin - SILODYX (CAP); UROREC (CAP) - PSUSA/00002701/202301

Applicant: Recordati Ireland Ltd

PRAC Rapporteur: Valentina Di Giovanni

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.51. Simoctocog alfa - NUWIQ (CAP); VIHUMA (CAP) - PSUSA/00010276/202301

Applicant: Octapharma AB

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.52. Somapacitan - SOGROYA (CAP) - PSUSA/00010920/202302

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.53. Sotrovimab (Xevudy) - XEVUDY (CAP) - PSUSA/00010973/202302

Applicant: Glaxosmithkline Trading Services Limited

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.54. Spesolimab - SPEVIGO (CAP) - PSUSA/00011033/202303

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.55. Teclistamab - TECVAYLI (CAP) - PSUSA/00011010/202302

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.56. Telotristat - XERMELO (CAP) - PSUSA/00010639/202302

Applicant: SERB S.A.S.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.57. Tezacaftor, ivacaftor - SYMKEVI (CAP) - PSUSA/00010730/202302

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.58. Ulipristal acetate[14] - ESMYA (CAP) - PSUSA/00009325/202302

Applicant: Gedeon Richter Plc.

[14] Indication(s) for the treatment of moderate to severe symptoms of uterine fibroids only

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.59. Upadacitinib - RINVOQ (CAP) - PSUSA/00010823/202302

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.60. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - PSUSA/00011009/202302

Applicant: BioMarin International Limited, ATMP[15]

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.61. Vosoritide - VOXZOGO (CAP) - PSUSA/00010952/202302

Applicant: BioMarin International Limited

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.62. Voxelotor - OXBRYTA (CAP) - PSUSA/00010983/202302

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Dexrazoxane - SAVENE (CAP); NAP - PSUSA/00001001/202302

Applicant: Clinigen Healthcare B.V. (Savene), various

[15] Advanced therapy medicinal product

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.2. Imiquimod - ALDARA (CAP); ZYCLARA (CAP); NAP - PSUSA/00001729/202301

Applicant: Viatris Healthcare Limited (Aldara, Zyclara), various

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

6.3.1. Acetylsalicylic acid, atorvastatin, ramipril (NAP) - PSUSA/00010280/202302

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.2. Beta-alanine (NAP) - PSUSA/00010510/202301

Applicant(s): various

PRAC Lead: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. Ciprofloxacin[16] (NAP) - PSUSA/00000776/202301

Applicant(s): various

PRAC Lead: Karen Pernille Harg

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.4. Dacarbazine (NAP) - PSUSA/00000919/202302

Applicant(s): various

PRAC Lead: Jan Neuhauser

[16] For topical use only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Etoposide (NAP) - PSUSA/00001333/202302

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Fenoterol, ipratropium (NAP) - PSUSA/00001367/202302

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Haemophilus type B and meningococcal group C conjugate vaccine (NAP) - PSUSA/00001583/202302

Applicant(s): various

PRAC Lead: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Haemophilus type B conjugate vaccines (NAP) - PSUSA/00001584/202302

Applicant(s): various

PRAC Lead: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Hydrochlorothiazide, losartan (NAP) - PSUSA/00001655/202302

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Hydroxyethyl starch (NAP) - PSUSA/00001694/202303

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Ibuprofen, ibuprofen lysine[17]; ibuprofen, caffeine (NAP) - PSUSA/00010649/202302

Applicant(s): various

PRAC Lead: John Joseph Borg

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Influenza vaccine (split virion, inactivated)[18] (NAP) - PSUSA/00010298/202303

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.13. Influenza vaccine (surface antigen, inactivated) (NAP) - PSUSA/00001744/202303

Applicant(s): various

PRAC Lead: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Ipratropium (NAP) - PSUSA/00001780/202301

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.15. Ipratropium, salbutamol (NAP) - PSUSA/00001781/202301

Applicant(s): various

PRAC Lead: Željana Margan Koletić

[17] Excluding the ductus arteriosus indication
[18] Non-centrally authorised product(s) only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Landiolol (NAP) - PSUSA/00010570/202302

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.17. Levosalbutamol, salbutamol (NAP) - PSUSA/00010330/202301

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.18. Lisdexamfetamine (NAP) - PSUSA/00010289/202302

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.19. Lomustine (NAP) - PSUSA/00001902/202301

Applicant(s): various

PRAC Lead: Anna Mareková

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.20. Mefloquine (NAP) - PSUSA/00001955/202302

Applicant(s): various

PRAC Lead: Karen Pernille Harg

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.21. Omega-3-acid ethyl esters (NAP) - PSUSA/00010312/202301

Applicant(s): various

PRAC Lead: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.22. Saccharomyces boulardii (NAP) - PSUSA/00009284/202302

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.23. Sodium citrate[19] (NAP) - PSUSA/00010986/202301

Applicant(s): various

PRAC Lead: Polona Golmajer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.24. Tick-borne encephalitis vaccine (inactivated) (NAP) - PSUSA/00002951/202301

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.25. Tauroselcholic [^{75}Se] acid (NAP) - PSUSA/00010486/202301

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Piperaquine tetraphosphate, artenimol - EURARTESIM (CAP) - EMEA/H/C/001199/LEG 018

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Martin Huber

[19] For extracorporeal use only

Scope: Submission of a cumulative review including a causality assessment regarding cases of haemolytic anaemia, as well as a cumulative analysis of all cases of delayed haemolytic anaemia with the use of oral artemisinin combination therapy from all available worldwide sources, since the last review until now, including a causality assessment

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Fondaparinux sodium - ARIXTRA (CAP) - EMEA/H/C/000403/II/0087

Applicant: Mylan Ire Healthcare Limited

PRAC Rapporteur: Mari Thorn

Scope: To update section 4.8 of the SmPC to update the ADR table following the assessment of PSUSA (EMEA/H/C/PSUSA/00001467/202112). The package leaflet is updated accordingly

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews[20]

None

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[21]

7.1.1. Chenodeoxycholic acid – CHENODEOXYCHOLIC ACID LEADIANT (CAP) - EMEA/H/C/PSA/S/0103.1

Applicant: Leadiant GmbH

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to PSA/S/0103: substantial amendment to a Cerebrotendinous Xanthomatosis Registry: long term non-interventional follow-up of safety and effectiveness of Chenodeoxycholic Acid Leadiant

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Lisocabtagene maraleucel – BREYANZI (CAP) - EMEA/H/C/PSA/S/0105

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP[22]

[20] Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
[21] In accordance with Article 107n of Directive 2001/83/EC
[22] Advanced therapy medicinal product

PRAC Rapporteur: Gabriele Maurer

Scope: Substantial amendment to a protocol for a non-interventional PASS of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma Grade 3B after 2 or more lines of systemic therapy in the post-marketing setting to characterise the incidence and severity of selected adverse drug reactions (ADRs), as outlined in the SmPC, and to monitor for potential clinically important adverse events (AEs) that have not yet been identified as part of the liso-cel safety profile

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Pomalidomide – IMNOVID (CAP) - EMEA/H/C/PSA/S/0106

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Monica Martinez Redondo

Scope: Substantial amendment to a non-interventional post authorisation registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Tabelecleucel – EBVALLO (CAP) - EMEA/H/C/PSP/S/0104.1

Applicant: Pierre Fabre Medicament, ATMP[23]

PRAC Rapporteur: Amelia Cupelli

Scope: MAH's response to PSP/0104 [An observational, PASS to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe] as per the request to supplementary information (RSI) adopted in May 2023

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[24]

7.2.1. Abrocitinib - CIBINQO (CAP) - EMEA/H/C/005452/MEA 003.3

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: MAH's response to MEA 003.2 [protocol for study B7451085: a drug utilisation study to evaluate the effectiveness of risk minimisation measures (RMMs) for abrocitinib in the EU using electronic healthcare data. The study objectives will be to evaluate indicators of HCP's adherence to the risk minimisation measures in accordance with the abrocitinib SmPC and prescriber brochure] as per the request to supplementary information (RSI) adopted in June

[23] Advanced therapy medicinal product
[24] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

2023

Action: For adoption of advice to CHMP

7.2.2. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/MEA 002.8

Applicant: AstraZeneca AB

PRAC Rapporteur: Željana Margan Koletić

Scope: MAH's response to MEA 002.7 [protocol amendment to Study D8220C00008: phase 3b, multicentre, open-label, single-arm in subjects with chronic lymphocytic leukaemia (ASSURE) to address missing information around moderate to severe cardiac impaired patients in subjects treated with Calquence (acalabrutinib)] as per the request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CHMP

7.2.3. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/MEA 007.14

Applicant: Sanofi Belgium

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH's response to MEA 007.13 [protocol for study OBS13434: a prospective, multicentre, observational, PASS to evaluate the long term safety profile of alemtuzumab treatment in patients with relapsing forms of multiple sclerosis (RMS)] as per the request for supplementary information (RSI) adopted in March 2023

Action: For adoption of advice to CHMP

7.2.4. Avalglucosidase alfa - NEXVIADYME (CAP) - EMEA/H/C/005501/MEA 007.2

Applicant: Sanofi B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH's response to MEA 007.1 [Protocol for study OBS17445 (listed as category 3 study in the RMP): a PASS to assess long term safety in patients with Pompe disease treated with avalglucosidase alfa in the commercial setting] as per request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CHMP

7.2.5. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/MEA 035.7

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: To evaluate the risk of hypocalcaemia (e.g., clinical characteristics, laboratory variables [PTH, Ca, and P], hospitalisation due to hypocalcaemia, co-medication, cinacalcet doses) in paediatric patients treated with cinacalcet

Action: For adoption of advice to CHMP

7.2.6. Cipaglucosidase alfa - POMBILITI (CAP) - EMEA/H/C/005703/MEA 001.1

Applicant: Amicus Therapeutics Europe Limited

PRAC Rapporteur: Mari Thorn

Scope: MAH's response to MEA 001 [protocol for study POM-005 of a non-imposed/non-interventional, listed as category 3 in the RMP: a global prospective observational registry of patients with Pompe disease] as per the request for supplementary information (RSI) as adopted in June 2023

Action: For adoption of advice to CHMP

7.2.7. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/MEA 003.4

Applicant: Merck Europe B.V.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: MAH's responses to MEA 003.3 [submission of a revised protocol for study MS700568-0004: pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study – CLEAR] as per the request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CHMP

7.2.8. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 007.8

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: From Initial MAA, RMP Category 3: A post-authorisation/post-marketing observational study using existing secondary health data sources to evaluate the association between exposure to AZD1222 and safety concerns (D8111R00006)

Action: For adoption of advice to CHMP

7.2.9. Coronavirus (COVID-19) vaccine (B.1.351 variant, prefusion Spike delta TM protein, recombinant) - VIDPREVTYN BETA (CAP) - EMEA/H/C/005754/MEA 002.2

Applicant: Sanofi Pasteur

PRAC Rapporteur: Jana Lukacisinova

Scope: MAH's response to MEA 002.1 [Submission of a protocol for study VAT 00007: Post-authorisation, observational study to assess the safety of VidPrevtyn Beta using routinely collected secondary data in Europe through VAC4EU. A non-interventional PASS to assess the occurrence of pre-specified AESIs and safety concerns following administration of VidPrevtyn Beta as a booster dose in a real-world setting] as per the request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CHMP

7.2.10. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 065.3

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: From II/0028: Study mRNA-1273-P910 Clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273

Action: For adoption of advice to CHMP

7.2.11. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 072.2

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH's response to MEA 0072.1 [protocol for study mRNA-1273-P919 (listed as category 3 study in the RMP): an observational study to assess maternal and infant outcomes following exposure to Spikevax during pregnancy and to assess whether the rate of pregnancy complications, adverse pregnancy outcomes, or adverse neonatal outcomes is associated with prenatal exposure to Spikevax] as per the request to supplementary information (RSI) adopted in May 2023

Action: For adoption of advice to CHMP

7.2.12. Empagliflozin - JARDIANCE (CAP) - EMEA/H/C/002677/MEA 004.7

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: MAH's response to MEA 004.6 and submission of a revised protocol for study 1245.97: a non-interventional PASS assessing the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes mellitus (T2DM): a multi-database European study as per the request for supplementary information (RSI) adopted in October 2022

Action: For adoption of advice to CHMP

7.2.13. Empagliflozin, metformin - SYNJARDY (CAP) - EMEA/H/C/003770/MEA 006.9

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: MAH's response to MEA 006.8 and submission of a revised protocol for study 1245.97: a non-interventional PASS assessing the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes mellitus (T2DM): a multi-database European study as per the request for supplementary information (RSI) adopted in October 2022

Action: For adoption of advice to CHMP

7.2.14. Eptinezumab - VYEPTI (CAP) - EMEA/H/C/005287/MEA 004.3

Applicant: H. Lundbeck A/S

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH's response to MEA 004.2 as per request for supplementary information adopted in May 2023 together with an updated protocol for an observational, historical cohort study of patients initiating eptinezumab in routine clinical practice and is investigating the long-term cardiovascular safety and real-world use of Eptinezumab

Action: For adoption of advice to CHMP

7.2.15. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/MEA 006.5

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 006.4 as per request for supplementary information adopted in May 2023 together with an updated protocol for PASS Study ALN-AS1-006: Company Sponsored AHP Registry: A global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)

Action: For adoption of advice to CHMP

7.2.16. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 033.7

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Mari Thorn

Scope: MAH's response to MEA 003.6 as per request for supplementary information adopted in March 2023 together with an updated protocol for an observational post-approval safety study of golimumab in treatment of polyarticular Juvenile Idiopathic Arthritis (pJIA) using the German Biologics JIA Registry (BiKeR)

Action: For adoption of advice to CHMP

7.2.17. Linzagolix choline - YSELTY (CAP) - EMEA/H/C/005442/MEA 002.1

Applicant: Theramex Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 002 as per request for supplementary information adopted in April 2023 together with an updated protocol for study YSELTY PASS: A multinational PASS on real-world treatment in patients receiving YSELTY (linzagolix choline) for moderate to severe symptoms of uterine fibroids, to evaluate routinely collected data on bone mineral density and to assess safety during long term (>12 months) use for linzagolix 200mg (with ABT) and 100mg (with and without ABT) dosing regimen

Action: For adoption of advice to CHMP

7.2.18. Naldemedine - RIZMOIC (CAP) - EMEA/H/C/004256/MEA 001.5

Applicant: Shionogi B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's response to MEA 001.4 as per request for supplementary information adopted in April 2023 for an Observational PASS of Patients with Chronic Opioid Use for Non-Cancer and Cancer Pain who have Opioid-Induced Constipation (OIC)

Action: For adoption of advice to CHMP

7.2.19. Pitolisant - OZAWADE (CAP) - EMEA/H/C/005117/MEA 003.1

Applicant: Bioprojet Pharma

PRAC Rapporteur: Kirsti Villikka

Scope: MAH's response to MEA 003 as per request for supplementary information adopted in April 2023 together with an updated protocol for study: a multi-center, observational prospective PASS to compare the cardiovascular risks and long-term safety of OZAWADE in patients with obstructive sleep apnoea treated or not by primary therapy and exposed or not to OZAWADE when used in routine medical practice

Action: For adoption of advice to CHMP

7.2.20. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 010.1

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Title: Long-Term Comparative Cohort Study in Patients with Crohn's Disease in a Real World Setting. Additional long-term data from the real-world experience of patients with Crohn's disease treated with risankizumab to assess product potential risks. A comparative cohort study will be conducted to estimate rates of malignancy (malignancy excluding NMSC, NMSC), serious infections, serious hypersensitivity reactions, and MACE in risankizumab treated patients with Crohn's disease, relative to alternative systemic therapies (e.g., biologics)

Action: For adoption of advice to CHMP

7.2.21. Somatrogon - NGENLA (CAP) - EMEA/H/C/005633/MEA 001.1

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of a revised protocol for study C0311023: an active surveillance study to monitor the real-world long-term safety of somatrogon among paediatric patients in Europe

Action: For adoption of advice to CHMP

7.2.22. Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/MEA 003.1

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Nathalie Gault

Scope: From Initial MAA: A 5-year active surveillance, PASS to characterise the safety of spesolimab for flare treatment in patients with GPP. Objectives: To evaluate the risks serious or opportunistic infections, systemic hypersensitivity reaction, malignancy, and peripheral neuropathy in adult patients (aged ≥18 years) experiencing a GPP flare who are treated with spesolimab or other treatments in the routine clinical care setting

Action: For adoption of advice to CHMP

7.2.23. Tezepelumab - TEZSPIRE (CAP) - EMEA/H/C/005588/MEA 001.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Eva Jirsová

Scope: PASS Study D5180R00010 (TREATY): A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with Severe Asthma Exposed to Tezepelumab

Action: For adoption of advice to CHMP

7.2.24. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 001

Applicant: Propharma Group The Netherlands B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for PASS Study TG1101-RMS402 (cat. 3): a long-term observational study of the safety and effectiveness of ublituximab in patients with relapsing multiple sclerosis, to assess the incidence of serious infections and malignancies in relapsing multiple sclerosis (MS) participants treated with ublituximab compared with other disease-modifying treatments (DMTs) observed longitudinally, to evaluate the long-term safety of ublituximab compared to other DMTs in patients with relapsing forms of MS in a real world setting and to assess long-term effectiveness of ublituximab compared with other DMTs in participants with relapsing forms of MS

Action: For adoption of advice to CHMP

7.2.25. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 002

Applicant: Propharma Group The Netherlands B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for PASS Study No TG1101-RMS403 (cat. 3): a registry study of pregnancy and infant outcomes in patients treated with ublituximab, to characterise the safety of ublituximab use in pregnancy, including maternal, foetal and neonate/infant outcomes, in female patients with relapsing forms of multiple sclerosis

Action: For adoption of advice to CHMP

7.2.26. Ublituximab - BRIUMVI (CAP) - EMEA/H/C/005914/MEA 003

Applicant: Propharma Group The Netherlands B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for PASS Study No TG1101-RMS404 (cat. 3): a study using data from an administrative healthcare claims database to characterise the safety to characterise the safety of ublituximab use in pregnancy, including maternal, foetal and neonate/infant outcomes, in female patients with relapsing forms of multiple sclerosis

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[25]

7.3.1. Oral retinoids (acitretin, alitretinoin, isotretinoin) (NAP) - EMEA/H/N/PSR/J/0040

Applicant (s): F.Hoffmann-La Roche Ltd. (on behalf of a consortium) (2CARE4GENERICS, ALFASIGMA ESPAÑA, ALLIANCE PHARMACEUTICALS, ALMIRALL, ARISTO PHARMA, AUROBINDO, BAILLEUL, BAUSCHHEALTH, DERMAPHARM, ENNOGEN HEALTHCARE, ESPECIALIDADES FARMACÉUTICAS CENTRUM, EXPANSCIENCE, FIDIA, GALENPHARMA, GAP, GSK, HEXAL, IASIS PHARMA, INDUSTRIAL FARMACÉUTICA CANTABRIA, ISDIN, MEDINFAR, MORNINGSIDE HEALTHCARE, MYLAN, ORIFARM, PELPHARMA, PHARMATHEN, PIERRE FABRE, ROCHE, SANOSWISS, LABORATOIRES SMB S.A., STADA, SUN PHARMA, TARGET, and TEVA)

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Final study report for a drug utilisation study to describe the prescribing practices before and after the update of the pregnancy prevention programme (PPP) for the oral retinoids acitretin, alitretinoin and isotretinoin in order to assess the effectiveness of these updated risk minimisation measures (RMMs) in women of childbearing potential, following an Article 31 referral on retinoid-containing medicinal products (EMEA/H/A-31/1446)

Action: For adoption of recommendation to CMDh (or request for supplementary information (RSI))

7.3.2. Prasterone – INTRAROSA (CAP) - EMEA/H/C/PSR/S/0044

Applicant: Endoceutics S.A.

PRAC Rapporteur: Menno van der Elst

Scope: Final study report for a drug utilisation study (DUS) to describe the baseline characteristics and utilisation patterns of EU postmenopausal women initiating treatment with Intrarosa and to assess whether EU prescribers abide by the contraindications stated in the EU SmPC

Action: For adoption of recommendation to CHMP (or request for supplementary information (RSI))

[25] In accordance with Article 107p-q of Directive 2001/83/EC

7.3.3. Valproate[26] (NAP) - EMEA/H/N/PSR/J/0043

Applicant: Sanofi-Aventis Recherche & Développement

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Final study report for a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring

Action: For adoption of recommendation to CMDh (or request for supplementary information (RSI))

7.4. Results of PASS non-imposed in the marketing authorisation(s)[27]

7.4.1. Cabozantinib - CABOMETYX (CAP) - EMEA/H/C/004163/II/0033

Applicant: Ipsen Pharma

PRAC Rapporteur: Menno van der Elst

Scope: Final report from study F-FR-60000-001 (CASSIOPE) listed as a category 3 study in the RMP: a prospective, non-imposed and non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy. The RMP version 7.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.2. Guanfacine - INTUNIV (CAP) - EMEA/H/C/003759/II/0033/G

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of the final reports from the drug utilisation study of Intuniv (guanfacine extended release) in European countries: a prescriber survey (EUPAS18739) and a retrospective database study (EUPAS18735), listed as category 3 studies in the RMP. The RMP version 4.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.3. Hydrocortisone - PLENADREN (CAP) - EMEA/H/C/002185/II/0043

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report from study SHP617-400 (EU AIR) listed as a category 3 PASS in the RMP; this is a European multi-centre, multi-country, post-authorisation, observation study (registry) of patients with chronic adrenal insufficiency. The RMP version 4.0 has also been submitted

[26] Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium
[27] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

Action: For adoption of PRAC Assessment Report

7.4.4. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/000717/II/0126

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: Submission of the final report from study CC-5013-MDS-010 listed as an obligation in the Annex II of the product information. This is a prospective non-interventional PASS, designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q). Section D of the Annex II and the RMP (version 39) are updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.5. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0023, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Jo Robays

Scope: Submission of the final report from study ACE-536-MDS-005 listed as a category 3 study in the RMP. This is a non-interventional PASS to evaluate the effectiveness of the additional risk minimization measure (aRMM) for Reblozyl among Healthcare Providers (HCPs) in the EU/EEA. The RMP version 3.0 has been submitted in order to reflect the completion of the study and to remove the HCP checklist as routine aRMM. The Annex II is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.6. Piperaquine tetraphosphate, artenimol - EURARTESIM (CAP) - EMEA/H/C/001199/II/0040/G

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from the effectiveness evaluation survey for Eurartesim (protocol no. 3366) listed as a category 3 study in the RMP. This is a European multi-centre online survey to assess physician understanding of the revised edition of the educational material. Consequential changes to RMP version 16.1 have been implemented with a submission of an updated RMP version 16.1 in order to delete 'severe malaria' from the Missing Information

Action: For adoption of PRAC Assessment Report

7.4.7. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0036

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of the final report from study 'EU survey of relevant healthcare professionals on understanding of key risk minimisations measures pertaining to

ILD/pneumonitis' listed as a category 3 study in the RMP. This is a non-imposed non-interventional PASS

Action: For adoption of PRAC Assessment Report

7.4.8. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/II/0101/G

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update of section 4.4 of the SmPC in order to remove a warning on cardiovascular events based on final results from non-interventional PASS studies NDI-MACE (CNTO1275PSO4005) and Quantify MACE (PCSIMM004697), listed as category 3 studies in the RMP (MEA/053 and MEA/054). NDI-MACE is a Nordic database initiative for exposure to ustekinumab: a review and analysis of major adverse cardiovascular events (MACE) from the Swedish and Danish national registry systems; Quantify MACE is an observational longitudinal PASS of STELARA in the treatment of psoriasis and psoriatic arthritis: analysis of major adverse cardiovascular events (MACE) using Swedish national health registers. The package leaflet is updated accordingly. The RMP version 27.1 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.9. Voriconazole - VFEND (CAP) - EMEA/H/C/000387/WS2270/0147

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Update of Annex II and RMP to version 6.0 to include the results from final clinical study report (CSR) following the completion of a non-interventional (NI) PASS A1501103: an active safety surveillance program to monitor selected events in patients with long-term voriconazole use - MEA091. In addition, the MAH is also taking this opportunity to introduce editorial changes

Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Apremilast - OTEZLA (CAP) - EMEA/H/C/003746/MEA 008.3

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Monica Martinez Redondo

Scope: Fourth yearly report for study CC 10004 PSA-012: evaluation of the long-term safety and safety outcomes for psoriatic arthritis patients treated with Otezla (apremilast) in the British Society for Rheumatology Psoriatic Arthritis Register (BSRBR-PsA) [final clinical study report (CSR) expected in Q2 2026]

Action: For adoption of advice to CHMP

7.5.2. Azathioprine - JAYEMPI (CAP) - EMEA/H/C/005055/MEA 001.1

Applicant: Nova Laboratories Ireland Limited

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Second annual report for category 3 study in the RMP: Monitoring of medication error reports specifically due to 'conversion of patients from tablet to liquid formulation and two dosing syringes' annually and submitted as post authorisation measure (PAM outside the context of azathioprine PSUR) (from initial opinion/MA)

Action: For adoption of advice to CHMP

7.5.3. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/ANX 010.1

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: Interim study results for Observational PASS to describe the long-term safety profile of first-relapse B-precursor acute lymphocytic leukaemia (ALL) paediatric patients who have been treated with blinatumomab or chemotherapy prior to undergoing haemopoietic stem cell transplant / Study 20180130

Action: For adoption of advice to CHMP

7.5.4. Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - EMEA/H/C/005808/MEA 004.4

Applicant: Novavax CZ, a.s.

PRAC Rapporteur: Gabriele Maurer

Scope: Interim report for study 2019nCoV-402: UK PASS Using the Clinical Practice Research Datalink (CPRD): A surveillance study to characterise the safety profile of Nuvaxovid in adults aged 18 years and older in the real-world setting using the UK CPRD

Action: For adoption of advice to CHMP

7.5.5. Dimethyl fumarate - SKILARENCE (CAP) - EMEA/H/C/002157/MEA 001.7

Applicant: Almirall S.A

PRAC Rapporteur: Mari Thorn

Scope: Fifth annual interim results for study M-41008-40 (listed as a category 3 study in the RMP): an observational PASS in European psoriasis registers to evaluate the long-term safety of Skilarence (dimethyl fumarate) used for the treatment of patients with moderate to severe psoriasis

Action: For adoption of advice to CHMP

7.5.6. Eliglustat - CERDELGA (CAP) - EMEA/H/C/003724/ANX 001.4

Applicant: Sanofi B.V.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Interim results for study OBS14009: A prospective multicentre observational post authorisation safety sub-registry to characterise the long-term safety profile of commercial use of eliglustat (Cerdelga) in adult patients with Gaucher disease

Action: For adoption of advice to CHMP

7.5.7. Elosulfase alfa - VIMIZIM (CAP) - EMEA/H/C/002779/ANX 005.8

Applicant: BioMarin International Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Ninth annual report for the Morquio A Registry Study (MARS): A voluntary observational registry study (MPS IVA)

Action: For adoption of advice to CHMP

7.5.8. Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/MEA 008.1

Applicant: Alexion Europe SAS

PRAC Rapporteur: Kimmo Jaakkola

Scope: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Biennial Interim Report, Protocol M07-001

Action: For adoption of advice to CHMP

7.5.9. Siponimod - MAYZENT (CAP) - EMEA/H/C/004712/MEA 004.3

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Interim study report for the survey among healthcare professionals and MS patients/caregivers (study CBAF312A2006)

Action: For adoption of advice to CHMP

7.5.10. Teduglutide - REVESTIVE (CAP) - EMEA/H/C/002345/ANX 003.10

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: MAH response to ANX 003.9 [Fourth interim report for study TED-R-13-002: an international short bowel syndrome registry - a prospective, long-term observational cohort study of patients with short bowel syndrome] as per request for supplementary information adopted in March 2023

Action: For adoption of advice to CHMP

7.5.11. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 041.3

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: MAH's responses to MEA 041.2 [Justification for not submitting an interim study report for study C4591036 (former paediatric heart network study): a safety surveillance study of myocarditis and myopericarditis associated with Comirnaty (tozinameran) in persons less than 21 years of age to characterize the clinical course, risk factors, long-term sequelae, and quality of life in children and young adults under 21 years with acute post-vaccine myocarditis, including a protocol amendment] as per request for supplementary information (RSI) adopted in March 2023

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Avatrombopag - DOPTELET (CAP) - EMEA/H/C/004722/MEA 002.6

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Monica Martinez Redondo

Scope: MAH’s responses to MEA 002.5 [feasibility assessment for study AVA-CLD-402: evaluation of the feasibility of conducting a PASS of Doptelet (avatrombopag) in patients with severe chronic liver disease (CLD) and of the use of potential European electronic health care databases] as per request for supplementary information adopoted in January 2023

Action: For adoption of advice to CHMP

7.7. New Scientific Advice

None

7.8. Ongoing Scientific Advice

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Dinutuximab beta - QARZIBA (CAP) - EMEA/H/C/003918/S/0053 (without RMP)

Applicant: Recordati Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Ebola vaccine (rDNA, replication-incompetent) - MVABEA (CAP) - EMEA/H/C/005343/S/0019 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.3. Ebola vaccine (rDNA, replication-incompetent) - ZABDENO (CAP) - EMEA/H/C/005337/S/0017 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.4. Tecovirimat - TECOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/S/0004 (without RMP)

Applicant: SIGA Technologies Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/R/0054 (without RMP)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.2. Etranacogene dezaparvovec - HEMGENIX (CAP) - EMEA/H/C/004827/R/0007 (without RMP)

Applicant: CSL Behring GmbH, ATMP[28]

PRAC Rapporteur: Menno van der Elst

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CAT and CHMP

8.2.3. Ex vivo expanded autologous human corneal epithelial cells containing stem cells - HOLOCLAR (CAP) - EMEA/H/C/002450/R/0058 (with RMP)

Applicant: Holostem Terapie Avanzate s.r.l., ATMP[29]

PRAC Rapporteur: Rhea Fitzgerald

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.4. Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/R/0026 (with RMP)

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Atazanavir - ATAZANAVIR KRKA (CAP) - EMEA/H/C/004859/R/0004 (with RMP)

Applicant: KRKA, d.d., Novo mesto

PRAC Rapporteur: Nathalie Gault

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Brexucabtagene autoleucel - TECARTUS (CAP) - EMEA/H/C/005102/R/0034 (with RMP)

Applicant: Kite Pharma EU B.V., ATMP[30]

[28] Advanced therapy medicinal product
[29] Advanced therapy medicinal product

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.3. Dacomitinib - VIZIMPRO (CAP) - EMEA/H/C/004779/R/0011 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.4. Febuxostat - FEBUXOSTAT KRKA (CAP) - EMEA/H/C/004773/R/0008 (with RMP)

Applicant: KRKA, d.d., Novo mesto

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.5. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - FLUCELVAX TETRA (CAP) - EMEA/H/C/004814/R/0040 (without RMP)

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Macimorelin - GHRYVELIN (CAP) - EMEA/H/C/004660/R/0020 (without RMP)

Applicant: Atnahs Pharma Netherlands B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Ropeginterferon alfa-2b - BESREMI (CAP) - EMEA/H/C/004128/R/0031 (without RMP)

Applicant: AOP Orphan Pharmaceuticals GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

[30] Advanced therapy medicinal product

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

None

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Oral retinoids (acitretin, alitretinoin, isotretinoin) (NAP) - DE/H/xxxx/WS/1115

Applicant(s): GAP AE (GAP SA) Beiname: G.A. Pharmaceuticals S.A. (on behalf od a consortium) (2CARE4GENERICS, ALFASIGMA ESPAÑA, ALLIANCE PHARMACEUTICALS, ALMIRALL, ARISTO PHARMA, AUROBINDO, BAILLEUL, BAUSCHHEALTH, DERMAPHARM, ENNOGEN HEALTHCARE, ESPECIALIDADES FARMACÉUTICAS CENTRUM, EXPANSCIENCE, FIDIA, GALENPHARMA, GAP, GSK, HEXAL, IASIS PHARMA, INDUSTRIAL FARMACÉUTICA CANTABRIA, ISDIN, MEDINFAR, MORNINGSIDE HEALTHCARE, MYLAN, ORIFARM, PELPHARMA, PHARMATHEN, PIERRE FABRE, ROCHE, SANOSWISS, LABORATOIRES SMB S.A., STADA, SUN PHARMA, TARGET, and TEVA)

PRAC Lead: Martin Huber

Scope: PRAC consultation on a worksharing variation (WS) procedure regarding the final study report of the category 3 PASS to assess the effectiveness of the Pregnancy Prevention Programme (PPP) for the oral retinoids acitretin, alitretinoin and isotretinoin, following an Article 31 referral on retinoid-containing medicinal products (EMEA/H/A-31/1446), on request of Germany

Action: For adoption of advice to Member States

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None

12.8. Planning and reporting

12.8.1. Marketing authorisation applications (MAA) forecast for 2023 – planning update dated Q3 2023

Action: For discussion

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla**Action:** For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

PRAC lead: Menno van der Elst

Action: For discussion

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. Patient Experience Data (PED) – priority activities and actions

Action: For discussion

12.21.2. International data standards: ISO planned update to the ICSR standard - opportunity to create new standard for electronic PSURs and RMPs

Action: For discussion

12.21.3. EMA-funded study - Association between COVID-19 vaccines and paediatric safety outcomes in children and adolescents in the Nordic countries – study results

Anders Peter Hviid (Statens Serum Institut)

Action: For discussion

12.21.4. PRAC drafting group on the risks of dependence and addiction of opioids - update

PRAC lead: Liana Gross-Martirosyan

Action: For discussion

12.21.5. Multi-stakeholder workshop on registries

PRAC lead: Patricia McGettigan

Action: For discussion

12.21.6. IRIS - update on variations, Art. 61(3) and Marketing authorisation transfers

Action: For discussion

13. Any other business

Next meeting on: 23-26 October 2023

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/